Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Eojin Kim

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

E. Kim1, M. Ryu2, S.R. Park2, M.Y. Beck3, W.J. Lee4, M.W. Lee4, Y. Kang5

Author affiliations

  • 1 Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 3 Department Of Oncology, Asan Medical Center, 05505 - Seoul/KR
  • 4 Department Of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
More

Resources

Background

To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a common and sometimes severe adverse event of imatinib treatment and may affect compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without interruption or dose reduction of imatinib. This phase II study was conducted to evaluate efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.

Methods

Between October 2014 and March 2016, 29 patients were enrolled and treated with oral prednisolone for imatinib-associated severe skin rash which was defined as grade 3 skin rash or grade 2 skin rash with pruritus. Prednisolone was started with 30mg daily for 3 weeks, and if skin rash is controlled, steroid was tapered over 12 weeks by determined schedule. The primary endpoint was treatment success rate (TSR). Treatment success was defined as maintaining imatinib without persistence or recurrence of skin rash requiring 1) additional systemic steroid treatment, and 2) interruption or dose reduction of imatinib.

Results

Of 29 patients enrolled, 16 patients (55.2%) received imatinib in adjuvant setting, and 13 (44.8%) in palliative setting. The median age was 61 years (range, 31-77). Eleven patients (37.9%) were male. Twenty-two patients (75.8%, TSR) were treated successfully, 2 (6.9%) were evaluated as treatment failures, and 5 (17.2%) were not evaluable. With a median follow-up of 22 months (range, 16.2-27.8), 71.5% of patients could maintain imatinib dose without recurrence of skin rash for 2 years. Patients aged <65 years showed higher TSR (odds ratio [OR]=4.38, p = 0.192). No one experienced disease progression during follow-up. All toxicities associated with systemic steroid were evaluated. One patient with myelodysplastic syndrome had Pneumocystis pneumonia. Otherwise, systemic steroid was well tolerated.

Conclusions

This study demonstrated that systemic steroid treatment can effectively control severe skin rash and minimize interruption or dose reduction of imatinib in GIST patients with imatinib-associated severe skin rash.

Clinical trial identification

NCT03440515.

Legal entity responsible for the study

Asan Medical Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings